01:02 , Aug 8, 2019 |  BC Extra  |  Company News

Aug. 7 Company Quick Takes: Panel backs narrower PrEP label for Descovy; plus Teva, Blueprint, DBV and more

FDA panel backs narrower PrEP label for Descovy FDA’s Antimicrobial Drugs Advisory Committee voted 16 to 2 that Gilead Sciences Inc. (NASDAQ:GILD) has provided sufficient evidence that Descovy emtricitabine/tenofovir alafenamide is safe and effective for...
21:22 , Jul 2, 2019 |  BC Extra  |  Financial News

July 2 Financial Quick Takes: Suspension continues for Woodford fund; plus CRUK, Codiak and Amarin

Woodford extends fund suspension  Woodford Investment Management Ltd. extended to July 29 the suspension of trading in its flagship fund, Woodford Equity Income Fund. The extension’s purpose is to allow the fund manager more time...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
01:50 , May 10, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

While the gut microbiome has attracted wide attention for its influence on anti-tumor immunity, a growing body of research suggests microbes living in the tumor itself may play even broader roles in cancer. At least...
20:00 , Apr 26, 2019 |  BC Week In Review  |  Clinical News

Cancer Research UK uses ctDNA profiling to stratify patients for early stage clinical trials

Cancer Research UK researchers used blood-based ctDNA profiling to match cancer patients with early stage clinical trials, reporting a preliminary efficiency of recruiting to a matched therapy of 11%. The researchers suggest that as more...
22:58 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

Mogrify is jumping ahead of the technologies that have propelled the stem cell field by creating a platform that bypasses intermediate steps, and opens the door to in vivo reprogramming. Cell Mogrify Ltd. uses small...
20:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

New Therapeutic Targets and Biomarkers: February 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February. Therapeutic targets are defined as any protein, gene or other molecule...
01:26 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest inhibiting the Wnt enhanceosome components BCL9, PYGO1 and/or PYGO2 could help treat APC-mutant colorectal cancer. In a mouse model of APC-mutant colorectal cancer, intestinal epithelium-specific knockout of BCL9, PYGO1...
19:35 , Jan 18, 2019 |  BioCentury  |  Emerging Company Profile

Achilles’ truncal neoantigens

Achilles Therapeutics Ltd. is developing a personalized T cell therapy that uses “truncal” neoantigens expressed in all tumor cells to drive T cells selected from tumor-infiltrating lymphocytes (TILs). Neoantigen discovery is fueling a burst of...
21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...